Skip to main content

Table 3 Changes in optical coherence tomography measurements by treatment group

From: Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series

 

Ranibizumab-aflibercept-ranibizumab treatment group (N = 10)

Wilcoxon p value

Friedman’s p value

Ranibizumab/bevacizumab-aflibercept-ranibizumab/bevacizumab treatment group (N = 9)

Wilcoxon p value

Friedman’s p value

 

Median (interquartile range)

Median (interquartile range)

  

Central macular thickness (CMT), μm

0.002

 

0.001

 OCT 1

335.5 (308.25–381.75)

283 (252.5–382.5)

 

 OCT 2

302.5 (222–360.75)

0.030a

285 (220.5–442.5)

0.38a

 OCT 3

375 (292.75–435.25)

0.016b

295 (216.5–392.5)

0.22b

 OCT 4

314 (232.5–399.75)

0.021c

248 (212.5–333.5)

0.037c

Total Fluid Volumed, mm3

0.007

 

0.003

 OCT 1

3.50 (2.47–5.52)

1.68 (0.71–5.28)

 

 OCT 2

3.55 (1.49–4.73)

0.121a

1.36 (0.58–4.20)

0.221a

 OCT 3

4.28 (2.94–6.27)

0.018b

0.96 (0.76–3.85)

0.297b

 OCT 4

2.87 (2.31–4.31)

0.024c

0.77 (0.47–2.72)

0.087c

Subretinal fluid (SRF), mm3

0.007

 

0.003

 OCT 1

0.11 (0.013–1.12)

0.16 (0.003–0.82)

 

 OCT 2

0.15 (0–0.76)

0.091a

0.11 (0.006–0.59)

0.077a

 OCT 3

0.68 (0.01–1.68)

0.178b

0.33 (0.04–1.15)

0.077b

 OCT 4

0.06 (0–0.40)

0.004c

0.09 (0.008–0.31)

0.038c

Intraretinal fluid (IRF), mm3

0.003

 

0.010

 OCT 1

0.04 (0–1.74)

0 (0–0.73)

 OCT 2

0.008 (0–0.07)

0.032a

0.0002 (0–0.49)

0.426a

 OCT 3

0.22 (0.0006–0.96)

0.012b

0 (0–0.59)

0.335b

 OCT 4

0.0009 (0–0.99)

0.206c

0 (0–0.44)

0.377c

Pigment Epithelial Detachment (PED), mm3

0.0003

 

0.003

 OCT 1

2.39 (1.77–3.23)

0.67 (0.18–3.85)

 OCT 2

2.36 (1.35–4.38)

0.222a

0.83 (0.20–3.40)

0.430a

 OCT 3

2.49 (1.90–4.13)

0.070b

0.86 (0.18–2.63)

0.107b

 OCT 4

2.39 (2.05–3.23)

0.480c

0.50 (0.16–2.03)

0.187c

  1. Treatment response of chronic neovascular age-related macular degeneration patients by treatment group: ranibizumab-aflibercept-ranibizumab vs. ranibizumab/bevacizumab-aflibercept-ranibizumab/bevacizumab
  2. Patients were divided into three treatment groups: those patients who had received bevacizumab only, then aflibercept, and then bevacizumab again (bevacizumab-aflibercept-bevacizumab), those patients who had received ranibizumab only, then aflibercept, and then ranibizumab again (ranibizumab-aflibercept-ranibizumab), and those patients who had received all three medications over the course of their treatment (ranibizumab/bevacizumab-aflibercept-ranibizumab/bevacizumab). The bevacizumab-aflibercept-bevacizumab group contained only two patients and was thus excluded from further analysis
  3. aComparing response from bevacizumab or ranibizumab (OCT 1) to aflibercept (OCT 2)
  4. bComparing progression while on aflibercept (OCT 2 and OCT 3)
  5. cComparing response back to bevacizumab or ranibizumab (OCT 4) from aflibercept (OCT 3)
  6. dSummation of subretinal fluid, intraretinal fluid, and pigment epithelial detachments